HFA Premium Access

The risk of all-cause death after COVID-19 hospital admission among patients with prior heart failure, chronic kidney disease and cardiorenal syndrome: a 12 month follow-up observational study

Congress Presentation

About the speaker

Doctor Johan Bodegard

AstraZeneca, Oslo (Norway)
1 presentation
0 follower

10 more presentations in this session

SCD and ventricular event rates in a Japanese population: Primary results from the Heart Failure Indication and Sudden Cardiac Death Prevention Trial

Speaker: Doctor K. Aonuma (Ibaraki, JP)

Thumbnail

Clinical course and related costs of patients with type 2 diabetes and heart failure and/or chronic kidney disease, drawn from a sample of more than 7 million people

Speaker: Professor A. Maggioni (Florence, IT)

Thumbnail

Potential Implications of Expanded FDA Labeling for Sacubitril/Valsartan in the United States

Speaker: Doctor M. Vaduganathan (Boston, US)

Thumbnail

Prescription Fill Patterns of Guideline-Directed Medical Therapies for Heart Failure During the COVID-19 Pandemic in the United States

Speaker: Doctor M. Vaduganathan (Boston, US)

Thumbnail

Higher Alkaline Phosphatase Mean and Variability Predict Heart Failure and All-cause Mortality

Speaker: Ms S. Lee (Shatin, HK)

Thumbnail

Access the full session

Registry Updates

Speakers: Doctor J. Bodegard, Doctor K. Aonuma, Professor A. Maggioni, Doctor M. Vaduganathan, Doctor M. Vaduganathan...
Thumbnail

About the event

Image

Heart Failure 2021

29 June - 1 July 2021

Sessions Presentations

ESC 365 is supported by

logo Novo Nordisk
logo Bristol Myers Squibb